Quick Summary
- Tilray delivered record quarterly net revenue of $206.7M in Q3, representing an 11% annual increase and surpassing analyst forecasts of $201.35M
- The company posted a surprise adjusted profit of $0.02 per share, dramatically exceeding the anticipated loss of -$0.14
- International cannabis sales jumped 73%, while total cannabis revenue climbed 19% to reach $64.8M
- Adjusted EBITDA expanded 19% to reach $10.7M; company maintains fiscal 2026 guidance range of $62M–$72M
- Company finalized BrewDog acquisition for approximately £40M and secured strategic Carlsberg collaboration beginning 2027
Tilray Brands delivered its strongest quarterly performance to date in the third quarter of fiscal 2026, generating net revenue of $206.7 million. This represents an 11% increase compared to the $185.8 million recorded during the corresponding period last year, surpassing analyst expectations.
$TLRY – Tilray Inc
Q3 2026🟩 Revenue: $206.73M Vs. $203M est.
🟩 Adj. EPS: $0.02 Vs. -$0.01 est👉 International cannabis surged 73% YoY, while distribution reached a record $83M, offsetting beverage weakness. pic.twitter.com/P20N5taXYa
— EarningsTime (@Earnings_Time) April 1, 2026
The real story was the earnings beat. Wall Street had projected a loss of 14 cents per share, but Tilray delivered an adjusted profit of $0.02 per share instead. Such a significant outperformance typically drives strong stock reactions, and TLRY responded with an 8.01% surge.
The company recorded a net loss of $25.2 million for the quarter, which appears negative on the surface but represents a dramatic turnaround from the staggering $793.5 million loss posted in the prior-year period.
Gross profit reached $55.0 million, marking a 6% year-over-year improvement, while the consolidated gross margin stood at 27%.
The cannabis division showed particularly impressive growth. Overall cannabis revenue expanded 19% to $64.8 million. International cannabis operations saw explosive growth with a 73% revenue surge, while cannabis flower sales volume doubled compared to the previous year.
In Canada, adult-use and medical cannabis revenue increased 8%, solidifying Tilray’s position as the country’s leading cannabis revenue generator.
The distribution business also performed exceptionally well, achieving a quarterly record of $83.0 million in net revenue. Distribution gross profit climbed to $10.0 million with margins improving to 12%.
Tilray successfully concluded its Project 420 synergy initiative during the quarter, achieving roughly $33 million in annual cost reductions.
Strategic Acquisitions and Partnerships
Following quarter-end, Tilray finalized its purchase of BrewDog, the prominent UK craft beer company, for roughly £40 million in cash. CEO Irwin Simon indicated the transaction enables the company to establish a “scaled global beverage platform.”
Additionally, Tilray announced a strategic collaboration with Carlsberg, scheduled to commence in 2027. According to the company, this partnership broadens its geographic footprint across Europe, the Middle East, Australia, Asia-Pacific, and North America.
Adjusted EBITDA for the third quarter totaled $10.7 million, representing a 19% increase from the $9.0 million reported in the comparable period.
Financial Outlook Maintained
Management reaffirmed its fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million. This projected range indicates growth between 13% and 31% versus fiscal year 2025 results.
Analyst consensus on TLRY currently stands at Hold, supported by one Buy recommendation and five Hold ratings issued within the last three months. The mean price target of $8.97 suggests potential upside of approximately 38.64% from current trading levels.
Notwithstanding the strong Q3 results, TLRY shares remain down 28.35% year-to-date and have declined 0.68% over the trailing twelve-month period.
